Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA, April 29, 2009 - Ambry Genetics announced today that it has successfully completed Illumina CSPro™ Certification for Genome Analyzer (GA) Sequencing, gaining entry to an elite group of Illumina Certified Service Providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
The Illumina CSPro™ is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro™ participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.
Ambry’s CSO, Anja Kammesheidt said, "the company has been working on the Illumina GA systems since January 2008. We are now offering Illumina CSPro™ Genome Analyzer (GA) Sequencing services to pharma, clinical and academic research groups, while keeping up with Illumina’s technology improvements. We value Illumina’s commitment to innovation and quality, and are excited to now be the second Illumina CSPro™ in the USA for the GA applications"
"Illumina CSPro™ recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Director of Corporate Marketing. "Ambry Genetics is now a Certified Service Provider able to offer Illumina Genome Analyzer Sequencing services using Illumina technology. Now that Ambry Genetics is a global CSPro™ partner, we are excited to work with them to make it easier for researchers to access the power of Illumina's genetic analysis technologies."
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com